Network Pharmacology, Molecular Docking, and Experimental Verification to Reveal the Mitophagy-Associated Mechanism of Tangshen Formula in the Treatment of Diabetic Nephropathy
Yinfeng Chen,Xiaying Wang,Jie Min,Jie Zheng,Xuanli Tang,Xiaoling Zhu,Dongrong Yu,De Jin
DOI: https://doi.org/10.2147/dmso.s443352
2024-02-14
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yinfeng Chen, &ast Xiaying Wang, &ast Jie Min, Jie Zheng, Xuanli Tang, Xiaoling Zhu, Dongrong Yu, De Jin Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310007, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dongrong Yu; De Jin, Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310007, People's Republic of China, Email ; Purpose: This study investigated the mechanism of TSF in treating DN through network pharmacology, molecular docking, and experimental validation. Methods: To identify critical active ingredients, targets, and DN genes in TSF, multiple databases were utilized for screening purposes. The drug-compound-target network was constructed using Cytoscape 3.9.1 software for network topological analysis. The protein interaction relationship was analyzed using the String database platform. Metascape database conducted enrichment analysis on the key targets using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The renoprotective effect was evaluated using a mouse model of diabetic nephropathy (db/db mice) that occurred spontaneously. Validation of the associated targets and pathways was performed using Western Blot (WB), Polymerase Chain Reaction (PCR), and Immunohistochemical methods (IHC). Results: The network analysis showed that the TSF pathway network targeted 24 important targets and 149 significant pathways. TSF might have an impact by focusing on essential objectives such as TP53, PTEN, AKT1, BCL2, BCL2L1, PINK-1, PARKIN, LC3B, and NFE2L2, along with various growth-inducing routes. Our findings demonstrated that TSF effectively repaired the structure of mitochondria in db/db mice. TSF greatly enhanced the mRNA levels of PINK-1. WB and IHC findings indicated that TSF had a notable impact on activating the PINK-1/PARKIN signaling pathway in db/db mice, significantly increasing LC3 and NRF2 expression. Conclusion: Our results indicate that TSF effectively addresses DN by activating the PINK-1/PARKIN signaling pathway and enhancing Mitochondrion structure in experimental diabetic nephropathy. Keywords: tangshen formula, diabetes nephropathy, network pharmacology, mitophagy, PINK1/Parkin pathway Diabetic Nephropathy (DN) is widely recognized as a significant contributor to end-stage renal diseases globally. 1 The prevalence of DN in China also shows a rapid growth trend. From 2009 to 2012, the prevalence of diabetic nephropathy in patients with type 2 diabetes in China was 30–50% in community patients. 2,3 Early identification, regulation of blood sugar levels, and strict control of blood pressure are the currently recommended approaches for managing DN, with a preference for utilizing angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. 4 However, it is well known that the progression of DN involves multiple mechanisms, such as the elevated activity of polyol and hexosamine pathways, excessive advanced glycation end products (AGEs), and protein kinase C (PKC) isoforms, and inadequate antioxidant defense. 5,6 These pharmacological treatments for DN may not effectively delay diabetic kidney damage in many clinical practices. In the past few years, a growing amount of research has examined the significance of mitophagy in DN. 7,8 Mitophagy, a specific type of autophagy responsible for eliminating damaged or surplus mitochondria, is crucial for maintaining the balance of cellular energy and is involved in kidney function. 8,9 According to recent studies, it has been indicated that as kidney damage advances, mitophagy may become overwhelmed or hindered, resulting in the accumulation of mitochondrial fragments and ultimately causing the death of cells. 8 This is confirmed in previous studies. In the model of type 1 diabetes in Ins2±AkitaJ mice, the renal function and tubular interstitial fibrosis could be enhanced by administering MitoQ orally. This enhancement is strongly associated with the upregulation of PINK/Parkin pathways, which are crucial in regulating mitophagy in renal tubules. 7,8 In the db/db mouse, activating PINK1/Parkin signaling by Astragalus could safeguard the kidneys against inflammation injuries. 9–12 These prove the pivotal roles of the PINK1/Parkin pathway as a cellular mitophagy gatekeeper in DN. Furthermore, the progression of DN can be delayed or improved by a therapy that controls mitophagy and the PINK1/Parkin pathway. Traditional Chinese medicine (TCM) has extensively treated DN and has shown positive clinical results. 13, -Abstract Truncated-
endocrinology & metabolism